Abstract
Introduction: The novel agents bortezomib and lenalidomide have demonstrated improved clinical outcomes in multiple myeloma (MM), yet most relapsed MM patients will become refractory to therapy. Methods: Pomalidomide is a second generation immunomodulatory agent that has been recently approved in the USA for the treatment of relapsed and refractory MM after two prior therapies, including lenalidomide and bortezomib. Results: Pomalidomide has several potential mechanisms of action which include anti-angiogenic effects, immunomodulation, an effect on the myeloma tumor microenvironment and the protein cereblon. Discussion: Several trials demonstrate the efficacy and safety of this novel compound in relapsed and refractory MM, including subjects refractory to lenalidomide and bortezomib. In the following review article, we discuss the role of pomalidomide as a new clinical treatment option for MM.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
